{"id":8606,"date":"2025-11-24T23:02:20","date_gmt":"2025-11-24T23:02:20","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/11\/24\/alzheimers-disease-johnson-and-johnson-posdinemab\/"},"modified":"2025-11-24T23:02:20","modified_gmt":"2025-11-24T23:02:20","slug":"alzheimers-disease-johnson-and-johnson-posdinemab","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/11\/24\/alzheimers-disease-johnson-and-johnson-posdinemab\/","title":{"rendered":"STAT+: J&amp;J\u2019s novel Alzheimer\u2019s drug fails in key trial, dimming hopes for a hot target"},"content":{"rendered":"\n<div>STAT+: J&#038;J\u2019s novel Alzheimer\u2019s drug fails in key trial, dimming hopes for a hot target<\/div>\n<p> \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>A promising Alzheimer\u2019s disease treatment from Johnson &amp; Johnson failed to slow the progress of the disease in a closely watched study, news that could dampen enthusiasm for a new class of potential medicines.<\/p>\n<p>J&amp;J terminated its mid-stage study of the injectable medicine posdinemab, the company said Friday, after an early look at results determined the treatment would not prove more effective than placebo. J&amp;J said it would present full data from the trial at a later date.<\/p>\n<p>Posdinemab\u2019s failure could cast a shadow over a cadre of in-development Alzheimer\u2019s treatments meant to improve on the standard of care. Biogen, UCB, and Voyager Therapeutics are developing similar treatments of their own.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/11\/24\/alzheimers-disease-johnson-and-johnson-posdinemab\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Damian Garde and Jason Mast<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/11\/24\/alzheimers-disease-johnson-and-johnson-posdinemab\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: J&#038;J\u2019s novel Alzheimer\u2019s drug fails in key trial, dimming hopes for a hot target A promising Alzheimer\u2019s disease treatment from Johnson &amp; Johnson failed to slow the progress of the disease in a closely watched study, news that could dampen enthusiasm for a new class of potential medicines. J&amp;J terminated its mid-stage study of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2705,2194,2154,2176,2155,2152],"tags":[2150],"class_list":["post-8606","post","type-post","status-publish","format-standard","hentry","category-alzheimers","category-biotech","category-biotechnology","category-pharma","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8606"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=8606"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8606\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=8606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=8606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=8606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}